NS2359 is a mixed monoamine reuptake inhibitor.  A study looked at the efficacy of NS2359 versus placebo in a double-blind randomized trial.

There was no statistical difference in the total ADHD-RS scale score between those taking NS2359 and placebo.  However, when looking at the inattentive type of ADHD, 41% of those who took NS2359 had an improvement, compared with 7% of the control group. 


Wilens, et al. (2008). A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD.  Behavioral and Brain Functions 4(24).